Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 687.48 Thousand USD | -9.67% |
| 2021 | 761.07 Thousand USD | -23.74% |
| 2020 | 998.05 Thousand USD | 7.07% |
| 2019 | 932.12 Thousand USD | -37.14% |
| 2018 | 1.48 Million USD | 170.44% |
| 2017 | 548.31 Thousand USD | 21546.66% |
| 2016 | 2533.00 USD | -91.4% |
| 2015 | 29.46 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 539.14 Thousand USD | -17.93% |
| 2023 Q1 | 656.93 Thousand USD | -4.44% |
| 2022 Q2 | 669.33 Thousand USD | -8.13% |
| 2022 FY | 687.48 Thousand USD | -9.67% |
| 2022 Q1 | 728.59 Thousand USD | -4.27% |
| 2022 Q4 | 687.48 Thousand USD | 6.81% |
| 2022 Q3 | 643.64 Thousand USD | -3.84% |
| 2021 Q2 | 700.36 Thousand USD | -25.4% |
| 2021 Q4 | 761.07 Thousand USD | 20.84% |
| 2021 Q3 | 629.82 Thousand USD | -10.07% |
| 2021 Q1 | 938.87 Thousand USD | -5.93% |
| 2021 FY | 761.07 Thousand USD | -23.74% |
| 2020 Q4 | 998.05 Thousand USD | 0.9% |
| 2020 FY | 998.05 Thousand USD | 7.07% |
| 2020 Q3 | 989.1 Thousand USD | -0.92% |
| 2020 Q2 | 998.29 Thousand USD | -2.08% |
| 2020 Q1 | 1.01 Million USD | 9.37% |
| 2019 Q4 | 932.12 Thousand USD | -12.84% |
| 2019 Q1 | 1.13 Million USD | -10.34% |
| 2019 Q3 | 1.06 Million USD | -1.08% |
| 2019 FY | 932.12 Thousand USD | -37.14% |
| 2019 Q2 | 1.08 Million USD | -5.12% |
| 2018 FY | 1.48 Million USD | 170.44% |
| 2018 Q4 | 1.27 Million USD | -14.29% |
| 2018 Q3 | 1.48 Million USD | 46.8% |
| 2018 Q2 | 1.01 Million USD | 16.38% |
| 2018 Q1 | 867.92 Thousand USD | 13.52% |
| 2017 Q2 | 2500.00 USD | 25.0% |
| 2017 FY | 548.31 Thousand USD | 21546.66% |
| 2017 Q4 | 764.53 Thousand USD | 39.43% |
| 2017 Q3 | 548.31 Thousand USD | 21832.4% |
| 2017 Q1 | 2000.00 USD | -16.35% |
| 2016 FY | 2533.00 USD | -91.4% |
| 2016 Q2 | 2341.00 USD | -80.06% |
| 2016 Q1 | 11.74 Thousand USD | -28.65% |
| 2016 Q3 | 2533.00 USD | 8.2% |
| 2016 Q4 | 2391.00 USD | -5.61% |
| 2015 FY | 29.46 Thousand USD | 0.0% |
| 2015 Q3 | 29.46 Thousand USD | -4.9% |
| 2015 Q2 | 30.97 Thousand USD | 0.0% |
| 2015 Q4 | 16.45 Thousand USD | -44.14% |
| 2014 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -29661.299% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 64.892% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 93.486% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -24.517% |
| Rebus Holdings, Inc. | 5000.00 USD | -13649.72% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.472% |
| Qrons Inc. | 420.00 USD | -163587.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 10.791% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 97.54% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -43.06% |
| Skye Bioscience, Inc. | 11.94 Million USD | 94.242% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.23% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 90.478% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -800.393% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.359% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 51.992% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -850.026% |
| Mesoblast Limited | 667.9 Million USD | 99.897% |
| Marizyme, Inc. | 22.01 Million USD | 96.877% |
| Genus plc | 1.02 Billion USD | 99.933% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 49.388% |
| Pharming Group N.V. | 462.85 Million USD | 99.851% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 79.249% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -37.762% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -9.647% |
| ContraFect Corporation | 20.67 Million USD | 96.675% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -76.113% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -79.887% |
| IMV Inc. | 31.33 Million USD | 97.806% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 83.418% |
| MultiCell Technologies, Inc. | 126.22 USD | -544572.794% |
| ONE Bio Corp. | 70.08 Million USD | 99.019% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 26.839% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.465% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -59.246% |
| Q BioMed Inc. | 3.51 Million USD | 80.444% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.046% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -163.125% |
| Biomind Labs Inc. | 73.81 Thousand USD | -831.313% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.846% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 52.549% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 97.71% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 74.967% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 73.591% |
| GB Sciences, Inc. | 103.44 Thousand USD | -564.61% |
| Alpha Cognition Inc. | 2.45 Million USD | 71.964% |
| HST Global, Inc. | 1526.00 USD | -44951.507% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 30.414% |
| Halberd Corporation | 10.13 Thousand USD | -6685.964% |
| Enzolytics Inc. | 361.7 Million USD | 99.81% |
| Agentix Corp. | 261.39 Thousand USD | -163.01% |
| Resverlogix Corp. | 8.11 Million USD | 91.528% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 63.39% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.985% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.559% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -7.477% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2917.804% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 92.318% |
| AVAX Technologies, Inc. | 7.37 Million USD | 90.681% |
| Zenith Capital Corp. | 7410.00 USD | -9177.814% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.98% |
| Ember Therapeutics, Inc. | 184.00 USD | -373533.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -113.634% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -163.038% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 25.914% |
| Kadimastem Ltd | 2.3 Million USD | 70.162% |
| Helix BioMedix, Inc. | 3.02 Million USD | 77.274% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.695% |
| BioStem Technologies, Inc. | 14.56 Million USD | 95.278% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1104.13% |
| LadRx Corporation | 2.3 Million USD | 70.211% |
| Cell Source, Inc. | 195.17 Thousand USD | -252.248% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -94.415% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -94.415% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1004.431% |
| Affymax, Inc. | 7.44 Million USD | 90.763% |
| Itoco Inc. | 1.4 Million USD | 50.896% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -618.699% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -548.572% |
| Mobile Lads Corp. | 52.00 USD | -1321988.462% |
| CytoDyn Inc. | 11.13 Million USD | 93.826% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -380.854% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -3745.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -78.35% |
| SYBLEU INC | 330.46 Thousand USD | -108.034% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -67.916% |
| International Stem Cell Corporation | 5.39 Million USD | 87.245% |
| Bioxytran, Inc. | 137.63 Thousand USD | -399.489% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 95.417% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 95.853% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -770.235% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 20.492% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 90.854% |
| Neutra Corp. | 2851.00 USD | -24013.855% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 97.879% |
| PureTech Health plc | 693.97 Million USD | 99.901% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 91.482% |
| IXICO plc | 15.84 Million USD | 95.661% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 91.699% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.335% |
| CSL Limited | 38.02 Billion USD | 99.998% |
| Cellectis S.A. | 333.99 Million USD | 99.794% |